The impact of GHR inhibition in GBM cell line was then assessed in vitro using both a pharmacological approach (GH‐G120K competitive antagonist) and a genetic knockdown (KD) using the CRISPR/Cas9 gene‐editing technology. This evidence concerns the gene GHR and glioblastoma.